Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Theuretzbacher

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|October 19, 2004
Pharmacokinetics/pharmacodynamics of echinocandinsU Theuretzbacher
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 28, 2017
Antibiotic innovation for future public health needsU Theuretzbacher
The Journal of Antimicrobial Chemotherapy|February 13, 2015
Antibiotic research and development: business as usual?S Harbarth, U Theuretzbacher, J Hackett, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 21, 2015
Use of old antibiotics now and in the future from a pharmacokinetic/pharmacodynamic perspectiveA E Muller, U Theuretzbacher, J W Mouton
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 8, 2016
Closing the evidence gap in infectious disease: point-of-care randomization and informed consentA Huttner, L Leibovici, U Theuretzbacher, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|December 30, 1999
Urinary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacinK G Naber, U Theuretzbacher, G Moneva-Koucheva, et al.
Antimicrobial Agents and Chemotherapy|July 14, 1998
Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteersK G Naber, U Theuretzbacher, M Kinzig, et al.
Intensive Care Medicine|April 15, 2017
The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infectionsT Tängdén, V Ramos Martín, T W Felton, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 28, 2020
Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteriaA N Kristoffersson, V Rognås, M J E Brill, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|October 19, 2004
Pharmacokinetics/pharmacodynamics of echinocandinsU Theuretzbacher
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 28, 2017
Antibiotic innovation for future public health needsU Theuretzbacher
The Journal of Antimicrobial Chemotherapy|February 13, 2015
Antibiotic research and development: business as usual?S Harbarth, U Theuretzbacher, J Hackett, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 21, 2015
Use of old antibiotics now and in the future from a pharmacokinetic/pharmacodynamic perspectiveA E Muller, U Theuretzbacher, J W Mouton
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 8, 2016
Closing the evidence gap in infectious disease: point-of-care randomization and informed consentA Huttner, L Leibovici, U Theuretzbacher, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|December 30, 1999
Urinary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacinK G Naber, U Theuretzbacher, G Moneva-Koucheva, et al.
Antimicrobial Agents and Chemotherapy|July 14, 1998
Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteersK G Naber, U Theuretzbacher, M Kinzig, et al.
Intensive Care Medicine|April 15, 2017
The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infectionsT Tängdén, V Ramos Martín, T W Felton, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 28, 2020
Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteriaA N Kristoffersson, V Rognås, M J E Brill, et al.
Pageof 1